SCHEMBL2174263

SCHEMBL2174263

O=C1O[C@H](COCc2ccccc2)[C@H](OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 0.56
ACHE P22303 2/20 0.56
HTR1A P08908 1/20 0.44
LMNA P02545 1/20 0.44
TACR2 P21452 3/20 0.43
NT5E P21589 1/20 0.43
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
SSTR1 P30872 1/20 0.40
SSTR2 P30874 1/20 0.40
SSTR4 P31391 1/20 0.40
SSTR3 P32745 1/20 0.40
SSTR5 P35346 1/20 0.40
PTPN1 P18031 5/20 0.39
CDC25B P30305 5/20 0.39
PTPN2 P17706 2/20 0.39
PTPN6 P29350 2/20 0.39
PTPN11 Q06124 2/20 0.39
PDPK1 O15530 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13112800 1.00 BCHE (0.56) BCHEACHEHTR1ALMNATACR2
SCHEMBL13956209 1.00 BCHE (0.56) BCHEACHEHTR1ALMNATACR2
SCHEMBL16027502 1.00 BCHE (0.56) BCHEACHEHTR1ALMNATACR2
SCHEMBL12407911 1.00 BCHE (0.56) BCHEACHEHTR1ALMNATACR2
SCHEMBL1087871 1.00 BCHE (0.56) BCHEACHEHTR1ALMNATACR2
SCHEMBL500473 1.00 BCHE (0.56) BCHEACHEHTR1ALMNATACR2
SCHEMBL18511226 1.00 BCHE (0.56) BCHEACHEHTR1ALMNATACR2
SCHEMBL22129916 1.00 BCHE (0.56) BCHEACHEHTR1ALMNATACR2
SCHEMBL22330780 1.00 BCHE (0.56) BCHEACHEHTR1ALMNATACR2
SCHEMBL13956220 1.00 BCHE (0.56) BCHEACHEHTR1ALMNATACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2076503-B1 C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES TAISHO PHARMACEUTICAL CO LTD (JP) 2013-07-17 EP disclosed
US-8236935-B2 Gem-difluorinated C-glycoside compounds derived from podophyllotoxin, their preparation and their applications INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (INSA) (FR) 2012-08-07 US disclosed
US-8236935-B2 Gem-difluorinated C-glycoside compounds derived from podophyllotoxin, their preparation and their applications INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (INSA) (FR) 2012-08-07 US disclosed
US-7973012-B2 C-phenyl glycitol compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-07-05 US disclosed
US-20100022460-A1 C-PHENYL GLYCITOL COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-01-28 US disclosed
US-20090318675-A1 NOVEL GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS DERIVED FROM PODOPHYLLOTOXIN, THEIR PREPARATION AND THEIR APPLICATIONS SUNSHINE BIOPHARMA INC. (CA) 2009-12-24 US disclosed
US-20090318675-A1 NOVEL GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS DERIVED FROM PODOPHYLLOTOXIN, THEIR PREPARATION AND THEIR APPLICATIONS SUNSHINE BIOPHARMA INC. (CA) 2009-12-24 US disclosed
US-20090311203-A1 GEM-DIFLUORIDE C-GLYCOPEPTIDE COMPOUNDS, THEIR PREPARATION AND USE PARTICULARLY FOR PRESERVATION OF BIOLOGICAL MATERIALS INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (INSA) (FR) 2009-12-17 US disclosed
EP-0701818-B1 Therapeutic methods using catalytic antibodies IGEN INT INC (US) 2003-07-30 EP disclosed
EP-0521996-B1 CATALYTIC ANTIBODY COMPONENTS IGEN INT INC (US) 2002-12-18 EP disclosed
US-5658753-A Catalytic antibody components WELLSTAT BIOCATALYSIS, LLC 1997-08-19 US disclosed
EP-0701818-A2 Therapeutic methods using catalytic antibodies IGEN, INC. (US) 1996-03-20 EP disclosed
EP-0436545-B1 THERAPEUTIC METHODS USING CATALYTIC ANTIBODIES IGEN INC (US) 1996-03-13 EP disclosed
EP-0521996-A4 CATALYTIC ANTIBODY COMPONENTS 1993-06-30 EP disclosed
EP-0521996-A1 CATALYTIC ANTIBODY COMPONENTS IGEN, INC. (US) 1993-01-13 EP disclosed
WO-1991014769-A1 CATALYTIC ANTIBODY COMPONENTS IGEN, INC. (US) 1991-10-03 WO disclosed
EP-0436545-A1 THERAPEUTIC METHODS USING CATALYTIC ANTIBODIES. IGEN INC (US) 1991-07-17 EP disclosed
EP-0436545-A4 THERAPEUTIC METHODS USING CATALYTIC ANTIBODIES. IGEN INC (US) 1991-05-30 EP disclosed
WO-1989010754-A1 THERAPEUTIC METHODS USING CATALYTIC ANTIBODIES IGEN, INC. (US) 1989-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022460-A1 C-PHENYL GLYCITOL COMPOUND SLC5A1, SLC5A2, SLC2A1 BCHE 1269/4885ACHE 3646/4885HTR1A 2185/4885
US-20090311203-A1 GEM-DIFLUORIDE C-GLYCOPEPTIDE COMPOUNDS, THEIR PREPARATION AND USE PARTICULARLY FOR PRESERVATION OF BIOLOGICAL MATERIALS B3GAT3, GMFG, GYPA BCHE 3025/4885ACHE 4679/4885HTR1A 4859/4885
US-20090318675-A1 NOVEL GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS DERIVED FROM PODOPHYLLOTOXIN, THEIR PREPARATION AND THEIR APPLICATIONS GLRA3, GMNN, B3GAT3 BCHE 2847/4885ACHE 2707/4885HTR1A 4160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.